Oncogene mechanismen van fusiegenen in hematologische aandoeningen : Oncogenic mechanisms of fusion genes in hematological malignancies

Autor: Vanden Bempt, M

T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive hematological disease, which arises from the malignant transformation of developing T-cell progenitors. Survival rates are nowadays up to 90% in children and 40% in adults. However, current

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______1131::cabd282b1b7fe711232883e4592c56c4
https://lirias.kuleuven.be/handle/123456789/628448

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

HOXA9 Cooperates with Activated JAK/STAT Signaling to Drive Leukemia Development.

Autor: de Bock CE; KU Leuven, Center for Human Genetics, Leuven, Belgium.; VIB, Center for Cancer Biology, Leuven, Belgium., Demeyer S; KU Leuven, Center for Human Genetics, Leuven, Belgium.; VIB, Center for Cancer Biology, Leuven, Belgium., Degryse S; KU Leuven, Center for Human Genetics, Leuven, Belgium.; VIB, Center for Cancer Biology, Leuven, Belgium., Verbeke D; KU Leuven, Center for Human Genetics, Leuven, Belgium.; VIB, Center for Cancer Biology, Leuven, Belgium., Sweron B; KU Leuven, Center for Human Genetics, Leuven, Belgium.; VIB, Center for Cancer Biology, Leuven, Belgium., Gielen O; KU Leuven, Center for Human Genetics, Leuven, Belgium.; VIB, Center for Cancer Biology, Leuven, Belgium., Vandepoel R; KU Leuven, Center for Human Genetics, Leuven, Belgium.; VIB, Center for Cancer Biology, Leuven, Belgium., Vicente C; KU Leuven, Center for Human Genetics, Leuven, Belgium.; VIB, Center for Cancer Biology, Leuven, Belgium., Vanden Bempt M; KU Leuven, Center for Human Genetics, Leuven, Belgium.; VIB, Center for Cancer Biology, Leuven, Belgium., Dagklis A; KU Leuven, Center for Human Genetics, Leuven, Belgium.; VIB, Center for Cancer Biology, Leuven, Belgium., Geerdens E; KU Leuven, Center for Human Genetics, Leuven, Belgium.; VIB, Center for Cancer Biology, Leuven, Belgium., Bornschein S; KU Leuven, Center for Human Genetics, Leuven, Belgium.; VIB, Center for Cancer Biology, Leuven, Belgium., Gijsbers R; Laboratory for Viral Vector Technology and Gene Therapy, Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium., Soulier J; U944 INSERM and Hematology Laboratory, St-Louis Hospital, APHP, Hematology University Institute, University Paris-Diderot, Paris, France., Meijerink JP; Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands., Heinäniemi M; Institute of Biomedicine, School of Medicine, University of Eastern Finland, Kuopio, Finland., Teppo S; Tampere Centre for Child Health Research, University of Tampere and Tampere University Hospital, Tampere, Finland., Bouvy-Liivrand M; Institute of Biomedicine, School of Medicine, University of Eastern Finland, Kuopio, Finland., Lohi O; Tampere Centre for Child Health Research, University of Tampere and Tampere University Hospital, Tampere, Finland., Radaelli E; KU Leuven, Center for Human Genetics, Leuven, Belgium.; VIB, Center for Cancer Biology, Leuven, Belgium., Cools J; KU Leuven, Center for Human Genetics, Leuven, Belgium. jan.cools@kuleuven.vib.be.; VIB, Center for Cancer Biology, Leuven, Belgium.

Publikováno v: Cancer discovery [Cancer Discov] 2018 May; Vol. 8 (5), pp. 616-631. Date of Electronic Publication: 2018 Mar 01.